Citations

Mayo Clinic

Clear

923 citation(s) found for "Wu, Claire".

Symptom assessment in patients with JAK inhibitor naïve and JAK inhibitor failed myelofibrosis.
Su, Yun , Woolfson, Adrian , Turnbull, Kathleen, Harrison, Claire , Scherber, Robyn M. , Shields, A. F., Krohe, Meaghan , Ojo, Funke, Pompilus, Farrah , Prchal, Josef T. , Jabbour, Elias , Shields, Alan, Mesa, Ruben A.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18559-e18559

10.1200/jco.2016.34.15_suppl.e18559 Get It

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial.
Harrison, Claire , Cervantes, Francisco , Dean, James , Wang, Lixia , Granston, Tanya, Yang, Yoojung, Mesa, Ruben A. , Vannucchi, Alessandro M. , Mead, Adam J.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7067-7067

10.1200/jco.2016.34.15_suppl.7067 Get It

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.
Egyed, Miklós , Szőke, Anita , Suvorov, Aleksandr , Perkins, Andrew C. , Mayer, Jiřı́ , Schouten, Harry C. , Tosi, Patrizia , Granston, Tanya, Nangalia, Jyoti , Harrison, Claire , Mesa, Ruben A. , Ganly, Peter S. , Farber, Charles Michael , Zachée, Pierre , Scheid, Christof , Dean, James P. , Kiladjian, Jean‐Jacques , Vannucchi, Alessandro M. , Mead, Adam J. , Perkins, Andrew C

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7065-7065

10.1200/jco.2016.34.15_suppl.7065 Get It

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.
Harrison, Claire , Egyed, Miklós , Szőke, Anita , Suvorov, Aleksandr , Perkins, Andrew C. , Mayer, Jiřı́ , Schouten, Harry C. , Tosi, Patrizia , Dean, James , Zhou, Huafeng, Nangalia, Jyoti , Ganly, Peter S. , Farber, Charles Michael , Zachée, Pierre , Scheid, Christof , Kiladjian, Jean‐Jacques , Vannucchi, Alessandro M. , Mead, Adam J. , Mesa, Ruben A. , Perkins, Andrew C

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7011-7011

10.1200/jco.2016.34.15_suppl.7011 Get It

Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
Niedzwiecki, Donna , Innocenti, Federico , Fruth, Briant, Greene, Claire, O’Neil, Bert H. , Atkins, James N., Horvath, Laura E., Polite, Blasé N. , Goldberg, Richard M. , Höchster, Howard S. , Blanke, Charles D. , Schilsky, Richard L. , Lenz, Heinz‐Josef , Niedzwiecki, Donna , Venook, Alan P. , Shaw, James Edward , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M. , Mayer, Robert J. , Bertagnolli, Monica M.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3504-3504

10.1200/jco.2016.34.15_suppl.3504 Get It

Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.
Harrison, Claire , Egyed, Miklós , Szőke, Anita , Suvorov, Aleksandr , Perkins, Andrew C. , Mayer, Jiřı́ , Schouten, Harry C. , Tosi, Patrizia , Zhou, Huafeng, Nangalia, Jyoti , Ganly, Peter S. , Farber, Charles Michael , Zachée, Pierre , Scheid, Christof , Dean, James P. , Kiladjian, Jean‐Jacques , Vannucchi, Alessandro M. , Mead, Adam J. , Mesa, Ruben A. , Perkins, Andrew C

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7066-7066

10.1200/jco.2016.34.15_suppl.7066 Get It

Randomized trial comparing a web-mediated follow-up via patient-reported outcomes (PRO) vs. routine surveillance in lung cancer patients: Final results.
Denis, Fabrice , Basch, Ethan , Lethrosne, Claire, Pourel, N. , Molinier, Olivier , Pointreau, Y. , Dômont, Julien , Bourgeois, Hugues , Senellart, Hélène, Urban, T. , Septans, Anne-Lise , Balavoine, Magal, Solal‐Céligny, Philippe , Basch, Ethan , Bennouna, Jaafar , Balavoine, Magali , Dueck, Amylou C. , Letellier, Christophe

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 6500-6500

10.1200/jco.2018.36.15_suppl.6500 Get It

Creation and validation of the “myMPN” prospective patient registry of myeloproliferative neoplasm patients.
Scherber, Robyn M. , Whyte, Lindsey, Woehrle, Michelle, Harrison, Claire , Dueck, Amylou C. , Verstovšek, Srđan , Mesa, Ruben A.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e19031-e19031

10.1200/jco.2018.36.15_suppl.e19031 Get It

Clinical evaluation of germline polymorphisms (SNPs) associated with disease response to capecitabine in metastatic breast cancer (MBC) (TBCRC 015).
Evans, Patrick , Morrow, Phuong K. , Storniolo, Anna Maria , Forero‐Torres, Andres , Poznak, Catherine Van , Merkel, Douglas E., Dees, Elizabeth Claire , Hahn, Olwen, Hoffman, Philip C., Nanda, Rita , O’Donnell, Peter H. , Choudhury, Noura J. , Ingle, James N. , Mayer, Ingrid A. , Fleming, Gini F. , Olopade, Olufunmilayo I. , Cox, Nancy J.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1071-1071

10.1200/jco.2018.36.15_suppl.1071 Get It

Abstract 221: Inherited variants at 3q13.33 and 3p24.1 influences risk of diffuse large B-cell lymphoma
Hildebrand, Michelle, Berndt, Sonja I. , Ghesquières, Hervé , McKay, James , Nieters, Alexandra, Cox, D. F., Monnereau, Alain , Brooks‐Wilson, Angela , Lan, Qing , Jackson, Rebecca D. , Crouch, Simon , Wu, Xifeng , Smedby, Karin E. , Salles, Gilles , Skibola, Christine F., Rothman, Nathaniel , Brooks-Wilson, Angela R , Salles, Gilles A , Kleinstern, Geffen , Vijai, Joseph , Wang, Sophia , Cox, David, Melbye, Mads , Teras, Lauren R. , Purdue, Mark P. , Vajdic, Claire M. , Albanes, Demetrius , Zeleniuch‐Jacquotte, Anne , Zhang, Yawei , Slager, Susan L. , Chanock, Stephen Jacob , Cerhan, James R.

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 221-221

10.1158/1538-7445.am2018-221 Get It

Abstract Background: We previously identified 5 SNPs at 4 susceptibility loci for diffuse large B-cell lymphoma (DLBCL) in individuals of European ancestry through a large genome-wide association study (Cerhan et al, Nat Gen 2014;46:1233-8); however, much of the heritability remains unexplained. To further elucidate genetic susceptibility to DLBCL, we sought to validate 2 loci at 3q13.33 and 3p24.1 that were suggestive in the original report. Methods: We selected two SNPs rs9831894 (3q13.33) and rs6773363 (3p24.1) for de novo replication from studies at the Mayo Clinic, MD Anderson, and Memorial Sloan Kettering. Logistic regression was used to estimate odds ratios (ORs), using a log-additive model, and adjusting for age, gender and significant eigenvectors for each genotyping center separately. For both SNPs, we then conducted a meta-analysis of all replication studies (n=3) and our original GWAS studies (n=4), encompassing in total 5662 cases and 9237 controls for rs9831894, and 5510 cases and 12,817 controls for rs6773363. Meta-analysis was conducted using the fixed-effects inverse variance method based on the β estimates and standard errors from each study. Results: In a meta-analysis of the 4 original GWAS scans (3856 cases and 7666 controls), rs9831894 (MAF=0.40) was associated with DLBCL risk (OR=0.84, P=4.52 x 10-9) and this replicated in a meta-analysis of the 3 studies with de novo genotyping (OR=0.80, P=4.17 x 10-5); the overall meta-analysis showed a strong association with DLBCL risk (OR=0.83, P=3.62 x 10-13). This locus maps near a plausible candidate gene, CD86, a protein coding gene and a member of the immunoglobulin superfamily that encodes a type I membrane protein. Binding of CD86 with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response, while binding of CD86 with CD28 antigen is a costimulatory signal for activation of the T-cell. In a meta-analysis of the same 4 GWAS scans, rs6773363 (MAF=0.45) was tentatively associated with DLBCL risk (OR=1.17, P= 3.68 x 10-7) and this replicated in a meta-analysis of the studies with de novo genotyping (OR=1.27, P=3.78 x 10-7); the overall meta-analysis showed a strong association with DLBCL risk (OR=1.20, P=2.31 x 10-12). This locus also maps near a plausible candidate gene, eomesodermin (EOMES), a transcription factor crucial for embryonic development of the central nervous system and also putatively involved in T-cell differentiation in viral infection defense. Conclusion: In this follow-up analysis of our initial GWAS, we have identified two additional loci associated with risk of DLBCL, the most common lymphoma subtype. These loci provide additional evidence for the role of immune function in the etiology of DLBCL. Citation Format: Geffen Kleinstern, Michelle Hildebrand, Vijai Joseph, Sonja I. Berndt, Hervé Ghesquières, James McKay, Sophia S. Wang, Alexandra Nieters, David Cox, Alain Monnereau, Angela R. Brooks-Wilson, Qing Lan, Mads Melbye, Rebecca D. Jackson, Lauren R. Teras, Mark P. Purdue, Claire M. Vajdic, Demetrius Albanes, Anne Zeleniuch-Jacquotte, Simon Crouch, Yawei Zhang, Susan L. Slager, Xifeng Wu, Karin E. Smedby, Gilles Salles, Christine F. Skibola, Nathaniel Rothman, Stephen J. Chanock, James R. Cerhan. Inherited variants at 3q13.33 and 3p24.1 influences risk of diffuse large B-cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 221.